[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613077":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":24,"centralContacts":29,"locations":34,"responsibleParty":54,"collaborators":58,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":70,"minAge":71,"maxAge":23,"enrollmentInfo":72,"targetDuration":23,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":37,"whyStopped":23,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Universitaire Ziekenhuizen KU Leuven","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients with a monogenic IEI with an hyperactive JAK-STAT pathway","Adult patients presenting with a genetically confirmed or highly suspected disorder leading to an exagerated JAK-STAT pathway.",[12],"Diagnostic Test: blood sampling",{"label":14,"type":6,"description":15,"interventionNames":16},"Healthy controls","Healthy controls (without immune-mediated disease)",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DIAGNOSTIC_TEST","blood sampling","Blood\u002Fserum samples will be collected during routine clinical visits at the time of planned peripheral venous blood sampling. Samples will be processed and either used immediately (flow cytometry-based cell sorting, gDNA extraction, in vitro functional assays, primary cell culture or single-cell applications) or stored for later analysis.",[14,9],null,[25],{"name":26,"affiliation":27,"role":28},"Rik Schrijvers, MD, PhD","UZ Leuven","PRINCIPAL_INVESTIGATOR",[30],{"name":26,"role":31,"phone":32,"phoneExt":23,"email":33},"CONTACT","+3216342985","rik.schrijvers@uzleuven.be",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University Hospitals Leuven,","RECRUITING","Leuven","Vlaams-Brabant","3000","Belgium","BE",{"type":44,"coordinates":45},"Point",[46,47],4.70093,50.87959,{"lat":47,"lon":46},[50],{"name":51,"role":31,"phone":23,"phoneExt":52,"email":53},"Cecilia Iglesias Herrero, MPharm","+34695118905","cecilia.iglesiasherrero@kuleuven.be",{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","prof. dr. Rik Schrijvers","Prof. dr.",[59],{"name":60,"class":6},"Research Foundation - Flanders (Fonds Wetenschappelijk Onderzoek)","100613077","ex-vivo-evaluation-of-jak-inhibitor-and-gene-therapeutical-approach-in-jak-stat-related-disorders-100613077",false,"NCT07261891","Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders","Ex Vivo Evaluation of JAK-inhibitor and Gene Therapeutical Approach in JAK-STAT Related Disorders (JAKarta Study)","JAKarta","Inclusion Criteria:\n\n* Cases (A): adult patients presenting with a genetically confirmed or highly suspected disorder leading to an exagerated JAK-STAT pathway.\n* Controls (B): participants eligible for inclusion in this study must fall in one of the following categories:\n* Healthy controls (without immune-mediated disease)\n\nExclusion Criteria:\n\n* Children (\\\u003C 18 years at time of recruitment)\n* Persons unable or unwilling to give informed consent",true,"ALL","18 Years",{"count":73,"type":74},20,"ESTIMATED","INTERVENTIONAL",[77],"NA","The investigators want to study the JAK-inhibitors and their impact on the immune system and evaluate the potential of a gene-therapeutic strategy",[80],"Primary Immunodeficiency Diseases (PID)",[82,83,84],"JAK inhibitors","STAT1 gain-of-function","gene therapy","2025-11-28",{"date":87,"type":88},"2025-12-03","ACTUAL",{"date":90,"type":88},"2024-11-21",{"date":92,"type":74},"2030-12-01",{"name":56,"class":6},1]